BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Celgene International Sárl (CELG) Release: Results from a Comparative Analysis Shows REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care


12/12/2011 6:07:15 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced results from a retrospective analysis to assess the risk of acute myeloid leukemia (AML) progression and death in REVLIMID (lenalidomide)-treated versus untreated patients with red blood cell (RBC) transfusion-dependent patients with IPSS Low or Int-1 risk myelodysplastic syndromes (MDS) with deletion 5q chromosome (with or without additional cytogenetic abnormalities). These results were presented during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->